Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk and studied in clinical trials both independently and in combination with semaglutide. Researchers use it to investigate the amylin receptor pathway’s role in metabolic regulation, appetite control, and body weight management.
What Is Amylin?
Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells in response to meals. It slows gastric emptying, suppresses postprandial glucagon release, and signals satiety through hypothalamic receptors. In people with type 2 diabetes or obesity, amylin secretion is often impaired. Native amylin has a short half-life and tendency to aggregate, which limits its research utility. Cagrilintide was engineered to address both limitations.
How Cagrilintide Differs From Native Amylin
Cagrilintide adds a fatty acid chain to the amylin backbone. This modification extends the half-life to approximately 7 days, enabling once-weekly administration in clinical research. It also reduces aggregation propensity. The extended half-life makes it a more practical tool for studying sustained amylin receptor activation compared to native amylin or pramlintide (the only approved amylin analogue as of 2026).
Research Applications
Cagrilintide acts on amylin receptors — primarily AMY1, AMY2, and AMY3, which are composed of calcitonin receptor subunits plus receptor activity-modifying proteins. In clinical studies, it produced dose-dependent reductions in body weight. Phase 2 data published in 2021 showed it reduced body weight by up to 10.8% versus placebo at the highest dose over 26 weeks. Its most studied application is in combination with semaglutide (the CagriSema combination), where Phase 3 trials reported weight reductions exceeding 22%.
Specifications
FenaLife supplies cagrilintide in 5mg and 10mg vials, each independently tested by Janoshik Analytical. Purity ≥98% HPLC. View COA here.
Frequently Asked Questions
Is cagrilintide the same as pramlintide?
No. Pramlintide is a shorter-acting amylin analogue requiring multiple daily doses. Cagrilintide is engineered for once-weekly administration through fatty acid conjugation.
What is the CagriSema combination?
CagriSema is the co-formulation of cagrilintide and semaglutide being studied in Phase 3 trials. It combines amylin receptor agonism with GLP-1 receptor agonism for additive metabolic effects.
Is this approved for human use?
No. This is a research-grade compound for laboratory use only.
Free shipping available?
Yes — free on all orders over $100.
For research use only. Not for human consumption, injection, or ingestion.